4.6 Review

Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development

Journal

PROCESSES
Volume 9, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/pr9010071

Keywords

binding free energy; computational pharmaceutics; computer-aided drug design; conformational ensemble; drug formulations; drug targets; enhanced sampling methods; ligand binding kinetics; protein flexibility; membrane interactions

Funding

  1. BioExcel CoE - European Horizon 2020 program [675728, 823830]
  2. Abo Akademi University research mobility program in the research profiling area of Drug Development and Diagnostics
  3. Abo Akademi University
  4. Tor, Joe and Pentti Borg's Foundation in 2020
  5. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes) [88881.162167/2017-01]
  6. Alexander von Humboldt Foundation
  7. Klaus Tschira Foundation
  8. European Union [839230]
  9. Orion Research Foundation sr.
  10. Vinnova [2017-02690]
  11. European Research Council [638965]
  12. Academy of Finland [315824]
  13. Academy of Finland (AKA) [315824, 315824] Funding Source: Academy of Finland (AKA)
  14. Marie Curie Actions (MSCA) [839230] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

This review provides a comprehensive overview of the current applications of MD in the drug development process, covering target validation, lead discovery, lead optimization, and pharmaceutical formulation development. The importance of MD in providing insights into drug targets, evaluating ligand-receptor interactions, and considering lipid bilayer environments in membrane protein simulations is highlighted. Additionally, the emerging role of MD in studying crystalline and amorphous solids, drug-polymer formulations, drug solubility, and nano-particle simulations is discussed.
Molecular dynamics (MD) simulations have become increasingly useful in the modern drug development process. In this review, we give a broad overview of the current application possibilities of MD in drug discovery and pharmaceutical development. Starting from the target validation step of the drug development process, we give several examples of how MD studies can give important insights into the dynamics and function of identified drug targets such as sirtuins, RAS proteins, or intrinsically disordered proteins. The role of MD in antibody design is also reviewed. In the lead discovery and lead optimization phases, MD facilitates the evaluation of the binding energetics and kinetics of the ligand-receptor interactions, therefore guiding the choice of the best candidate molecules for further development. The importance of considering the biological lipid bilayer environment in the MD simulations of membrane proteins is also discussed, using G-protein coupled receptors and ion channels as well as the drug-metabolizing cytochrome P450 enzymes as relevant examples. Lastly, we discuss the emerging role of MD simulations in facilitating the pharmaceutical formulation development of drugs and candidate drugs. Specifically, we look at how MD can be used in studying the crystalline and amorphous solids, the stability of amorphous drug or drug-polymer formulations, and drug solubility. Moreover, since nanoparticle drug formulations are of great interest in the field of drug delivery research, different applications of nano-particle simulations are also briefly summarized using multiple recent studies as examples. In the future, the role of MD simulations in facilitating the drug development process is likely to grow substantially with the increasing computer power and advancements in the development of force fields and enhanced MD methodologies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available